Á¿×Ó¹²Õñ¼ì²â,Quantum resonance detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¦ÅßÄòÄÒĤÊÔÑé,chick embryo chorioallantoic membrane assayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö·Ö×Ó±êÖ¾Îï,molecular tumor markersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´ÅÈÈÁÆ,magnetic mediated hyperthermiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Gardner×ÛºÏÕ÷,Gardner's syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²ÊÔÑéÉè¼Æ,design of clinical trialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÔ´ÐÔ¹ÇÈí»¯Ö¢,oncogenic osteomalaciaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²Ñо¿½øÕ¹,Current clinical research progressÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« PI3K/Akt/mTOR,PI3K/Akt/mTOR signal pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÇ»´©´ÌÒýÁ÷,Thoracentesis and drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÐØ»ýÒº,Malignant pleural effusion Double-draining waysÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ìÍÑÑõµ¨ËáÑÜÉúÎï,chenodeoxycholic acid derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾«È·ÖÎÁÆ,accurate therapy of cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹HER2µ¥¿¹,anti-HER2 monoclonal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ý¼«ÖÎÁÆ,aggressive manage mentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èý½×ÌÝֹʹ·¨,The three steps analgesic ladder for cancer pain managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑøѪ½ºÄÒ,Yangxue capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾±ÇåÊõ,residual / recurrent cervical metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÖÜÆÚÒÀÀµÐÔ¼¤Ã¸4,CDK 4Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÂð·È»ºÊÍƬ,morphine hydrochloride sustained-release tabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÒÌ«Äá͸ƤÌù,Fentany transdermal patchÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÐظ¹Ç»»ýÒº,malignant hydrothorax and seroperitoneumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÀ·Æ¿µ,morphine hydrochloride sustained-release tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍâÖÜѪµ¥ºËϸ°û(PBMC),periphera blood mononuclear cell(PBMC)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« СԲϸ°û,Roundlet cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ѪÁ÷¹à×¢ÂÊ,blood flow perfusion rateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ì¥Å̶àëÄ,placenta polypeptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« º¬²¬·½°¸,platinum containing regimensÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔçÊìȾɫÌåÄý¼¯,premature chromosome condensationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ½¬Ä¤Ç»»ýÒº,Malignant serous effusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌØÒìÐÔÊÜÌå,specific receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °×ϸ°û½éËØ2/ͶҩºÍ¼ÁÁ¿,interleukin-2/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇÖ×Áö/·ÅÉäÐÔºËËØÏÔÏñ,bone neoplasms/radionuclide imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÅàÑøÒº,culture medium for cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 3H-TdRÊÍ·Å·¨,~ 3H-TdR methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×Ô¿Øֹʹ±Ã,auto-controlled analgesicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹Ä¤ºóÖ×Áö/²¡Àíѧ,retroperitoneal neoplasms/pathologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·´ÒåSurvivinºËËá,Antisense Survivin RNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÐÀÏÄ껼Õß,middle and old aged patientsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÓªÑøÒò×ÓÊÜÌå,neurotrophic factor receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ö×ÁöЧ¹û,Antitumor responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Éñ¾­Ôª¿¹Ìå,anti-neuronal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ƥ·ôתÒÆ°©,cutaneous metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ°°×оƬ¼ì²âϵͳ,protein chip assay systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö¹ÍÂÁÆЧ,antiemetic effectÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûӡƬ,Imprint smearÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÒÌ«ÄáÌù¼Á,Fentanyl SystemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÔöÉú¼äƤϸ°û,Reactive mesothelial cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÇ»ÄÚ¸øÒ©,chest cavity administrationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ðز¿¶ñÐÔÖ×Áö,thoracic malignant tumourÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÎÓú±ê×¼,curative criteriaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÇ»ÄÚ¹à×¢,intrathoracic instillationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Íç¹ÌÐÔ°©Í´,chronic cancerous painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« rhIL-13,recombinant human interleukin-13(rhIL-13)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ˨˨ÈûÖ¢,thromboembolic diseasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áöϸ°û½þÈó,invasion of tumor cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¹ÅèÇ»,peritoneal and pelvicÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ÷Ç¿ÖÎÁÆ,intensity modulated therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÔ­·¢ÐÔ°©,Multiple primary cancersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÀÏÄê°©Ö¢,The old cancerousÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÇ»ÄÚ×¢Ò©,pleural plenracotomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Һ̬¼î½ðÊô,liquid alkali metalsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¸ºÎÆ«²î,geometry warpÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ò½ÔºÖÐ×ÓÕÕÉäÆ÷,clinical neutron irradiatorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« H_(22)¸Î°©Ï¸°û,H_(22) hepatomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¼Êõ³ÉÊì,technology ripeningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö²¡¶¾,tumorigenic virusesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ù·ÖÀàÆ÷,base classifiersÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐÅÏ¢»ñÈ¡ÐÐΪ,information acquirement behaviorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼ÁÁ¿Ñ§ÌØÐÔ,Dosimetric characteristicsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÒò×è¶ô,gene repressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ÐÏò¶¨Î»,targeted localizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉýÎÂЧӦ,Temperature elevationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÖ×Áöϸ°û,malignant tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÏÖªÀú³Ì,cognition processesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °¬Êϸ¹Ë®Áöϸ°û,Ehrlich ascites tumor cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ׸øҩϵͳ,nanometer drug delivery systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸±Áö×ÛºÏÕ÷,paraneoplatic syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÖ×Áö¹ÇתÒÆ,malignancy bone metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÙ¼ûÕ÷Ïó,rare manifestationsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½¡Æ¢ÒæÉö¿ÅÁ£,Jianpiyishen GranulesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼±ÐԷǵÈÈÝÁ¿ÑªÒºÏ¡ÊÍ,Acute non-isovolemic hemedilutionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¤ÆÚÐÔ¶ñÐÄÅ»ÍÂ,anticipatory nausea and vomitingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« UPRT»ùÒò,UPRT geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ǶºÏÃâÒßÊÜÌå,chimeric immune receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Raf¼¤Ã¸Àà,raf kinasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸¨ÖúÕòÍ´,relieve painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ç»ÄÚ»¯ÁÆ,Intracavitary chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ìåλ¹Ì¶¨¼¼Êõ,technique of immobilizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« H22ºÉÁöСÊó,H22 hepatoma-bearing miceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂËÅÝÊ÷ͻ״ϸ°ûÈâÁö,follicular cell sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÍÑàÑßÊ/ÍÑà×ऺËËáÄÚÇÐø/Ñõ»¯»¹Ô­Òò×Ó-1,Apurinic / apyrimidinic endonuclease / redox factor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ðز¿·ÅÁÆ,thoracic radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÉÃ×ÔØÌåÒ©Îï,nanocarrier drugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹Ç΢»·¾³,bone microenvironmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¹Ñª·½,drugs for enriching blood,nourishing blood formulasÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNA¾ÛºÏø¦Æ,DNA polymerase ¦ÆÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌåÄÚ¿¹Ö×Áö»îÐÔ,in vivo efficacyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µòÍöÏÔÏñ,apoptosis imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Æ¢Éö·½,Pi shenfangÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 7 8 9 10 11 12 13 14 ÉÏÒ»Ò³